The HPV vaccine is a preventive immunization designed to protect against human papillomavirus (HPV) infections, which can lead to cervical, vaginal, and vulvar cancers, as well as genital warts.
This vaccine targets high-risk HPV strains, including HPV 16 and HPV 18, which are strongly associated with cervical and other HPV-related diseases. By stimulating an immune response, it reduces the likelihood of infection and subsequent disease development.
Recommended Age Group: Individuals aged 9 to 45, with the highest efficacy observed when administered before sexual activity begins.
At-Risk Individuals: Those with multiple sexual partners or a higher likelihood of HPV exposure may benefit from vaccination as part of their preventive healthcare strategy.
The HPV vaccine is administered in three doses to establish long-term immunity:
First Dose: Initiates the immune response.
Second Dose: Administered 1 to 2 months after the initial dose to reinforce immune protection.
Third Dose: Given 6 months after the first dose to ensure sustained immunity.
The HPV vaccine has a strong safety profile, with localized soreness at the injection site being the most common mild side effect. Importantly, it does not affect fertility, as its sole function is to prevent HPV-related infections.
Malaysia
